Nice | Ticagrelor for the treatment of acute coronary syndrome ACS

4th November 2011 by Louise Hudman

Ticagrelor is a PO drug which inhibits platelet aggregation. In combination with aspirin it is more effective than clopidogrel + aspirin at reducing the endpoint of MI or death from vascular events.

It will be started by secondary care and continued by cardiologists, so we shouldn’t really have to initiate it.

It will be started in patients who’ve had a STEMI where primary percutaneous coronary intervention (PCI) is considered and also in patients with a NSTEMI who have certain other risk factors.

Read more

No credit card details needed – it takes two minutes.

Join free trial

Login

Already a member? Login to view this content.

Login

"I am so glad and grateful for being a member of NASGP's BOB Locum Chambers. I started with them in a critical period of my career as I was a newly-qualified GP, looking for work in a new area with a new virus hardly hitting the world and the jobs market.

NASGP chair Dr Richard Fieldhouse and Membership Support Manager Ali Lewis's help was a godsend. They introduced me to locum work in a friendly and kind manner, provided valuable support and excellent service through the ever-improving LocumDeck and NASGP website. With the help of the chambers, I received a face to face tutorial on Emis (I trained on SystmOne) and my online profile was promoted on a growing network of GP practices throughout Buckinghamshire, Oxford and Berkshire.

I was able to work in different GP practices with different staff and patient demographics, massively increasing my clinical experience, resilience and communication skills.

It also helped me funnelling down all the job offers I received through my locum work until I recently agreed for a salaried position in a GP practice that I love working at. "

Dr Nazar Ahmed, GP, Oxford

See the full list of features within our NASGP membership plans

Membership